Multi-centre eczema treatment study including 3% boric acid solution
Eczema
Enrolment: 342 · Results not recorded
Loading the evidence…
Drug · ATC S02AA03; inorganic, natural product and therapeutic flags set; max_phase 3, no first_approval recorded. get_mechanism was NOT called within the time budget, so moa_list is empty by OMISSION not by negative result. Sodium pentaborate pentahydrate was NOT separately searched and the hydrogel formulation has no ChEMBL entity, so this is a PARTIAL identity for boric acid only. All recorded trials are topical antimicrobial use in otomycosis, vulvovaginal candidiasis or eczema; NONE is a wound-healing or trauma indication.
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Eczema
Enrolment: 342 · Results not recorded
Candidiasis, Vulvovaginal
Enrolment: 120 · Results not recorded
Otomycosis
Enrolment: 120 · Results not recorded
Otomycosis
Enrolment: 100 · Results not recorded
Otomycosis
Enrolment: 60 · Results not recorded
Vulvovaginal Candidiasis
Enrolment: 76 · Results not recorded
1 studies reported at therapy level; 1 evidence entries itemised.
Model: Full-thickness excisional skin wound in streptozotocin-induced diabetic rats
Both boron compounds increased dermal cell proliferation, migration and growth factor and gene expression with marked antimicrobial activity, sodium pentaborate pentahydrate being the more active. The sodium pentaborate pentahydrate gel improved wound healing rate and histopathological scores in di…
Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.